A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With Diabetes
Status:
Completed
Trial end date:
2019-12-19
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind, placebo-controlled, parallel-group trial investigating
the effect of 4 weeks bi-daily dosing of XEN-D0501 on blood glucose reduction as add-on to
metformin in patients with diabetes mellitus type 2 where life style changes and treatment
with metformin has failed to effectively reduce blood glucose concentrations.